Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2043

Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.

Patents
1,718

Quick answer

1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 11666594

    Antibody-drug conjugates comprising a cyclic dinucleotide

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11667903

    Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11667628

    Compounds for imaging tau proteins that accumulate in brain

    National Institutes for Quantum and Radiological Science and Technology · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11666663

    Hexameric tetrahedral RNA nanostructures

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11666653

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11667718

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11667702

    Stable aqueous formulations of aflibercept

    Coherus BioSciences, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11667692

    T cell receptors recognizing HLA-CW8 restricted mutated KRAS

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11666612

    Network-based microbial compositions and methods

    Seres Therapeutics, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11666536

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11666660

    Glycan-dependent immunotherapeutic molecules

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11667612

    Compositions and methods for delivering pharmaceutical agents

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11666602

    Treatment of pulmonary arterial hypertension with mesenchymal stem cells

    United Therapeutics Corporation · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11666547

    Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)

    Northwestern University · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11666528

    Drug implants containing enzalutamide and methods of use thereof

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11666574

    Combination therapy involving diaryl macrocyclic compounds

    TURNING POINT THERAPEUTICS, INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11666637

    Insulin-loaded metal-organic frameworks

    Northwestern University · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11666671

    Spatial mapping of kidney functions

    Northwestern University · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11666661

    Methods and compounds for targeted autophagy

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11667900

    Compositions and methods for enhancing macrophage-mediated antibody guided cancer cell or tumor eradication

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11667662

    Modulators of 5′-nucleotidase, ecto and the use thereof

    Arcus Biosciences, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11666596

    Nucleotide, polypeptide and applications thereof

    THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11666557

    Triazolone compounds and uses thereof

    TEMPEST THERAPEUTICS, INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11667924

    Increasing levels of nicotinic alkaloids in plants

    22ND CENTURY LIMITED, LLC · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 2023174645

    ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS

    DISC MEDICINE INC [US] · Granted Thu Jun 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11673966

    Monoclonal and humanized antibodies to a cancer glycopeptide

    The Board of Regents of the University of Texas System · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11673967

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11673954

    Single-domain antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11674177

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11672832

    Development of amnion-like tissue from human pluripotent stem cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11673902

    Isoindolinone and indazole compounds for the degradation of EGFR

    C4 THERAPEUTICS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11673953

    DLL3 targeting chimeric antigen receptors and binding agents

    Allogene Therapeutics, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11674968

    Methods for identifying free thiols in proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11672793

    Compositions of CXCR4 inhibitors and methods of preparation and use

    X4 Pharmaceuticals, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11672794

    Therapeutic targeting of the BAP1 complex in cancer

    Northwestern University · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11672791

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11672811

    Materials and methods for suppressing and/or treating bone related diseases and symptoms

    The United States of America as Represented by the Department of Veteranas Affairs · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11672775

    Treprostinil prodrugs

    United Therapeutics Corporation · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11672762

    Onapristone extended-release compositions and methods

    CONTEXT BIOPHARMA, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11672776

    Multi-arm polymeric alkanoate conjugates

    Nektar Therapeutics · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11672863

    Enhanced solubility drug-containing formulations

    United Therapeutics Corporation · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11673899

    Crystal form of thieno[2,3-c]pyridazine-4(1H)-one compound, preparation method therefor and use thereof

    Medshine Discovery Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11673887

    N-acyl amino acid compounds and methods of use

    Pliant Therapeutics, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11674159

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11674139

    Oligonucleotides for treating expanded repeat diseases

    Sarepta Therapeutics, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11674121

    Platform for generating safe cell therapeutics

    The Regents of the University of California · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11673853

    Small molecule AMPK activators

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2043?

1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.